BOSTON--(BUSINESS WIRE)--The DNA Repair Company (DNAR), an emerging company focused on personalized approaches to cancer treatment, today announced promising early clinical data for identifying effective treatment regimens for head and neck cancer. An analysis of DNA repair protein biomarkers was performed in collaboration with the University of Chicago Medical Center that identified biomarker combinations as novel predictors of response to treatment with induction chemotherapy and overall survival. The data were presented yesterday by the lead investigator Tanguy Seiwert, MD, Department of Medicine, Section of Hematology/Oncology, from The University of Chicago at the 44th Annual American Society for Clinical Oncology Meeting. The study’s senior author was Everett Vokes, MD, also from the University of Chicago.
